Supplementary Material
Figure S1. Flow diagram of participants in the study Responded to letters/advertisements (n=2560) Screening visits (n=542) Randomized (n=373) 400 IU daily (n=124) Completed 3 years of treatment (n=113) Discontinued treatment (n=11) -5 adverse events -3 personal reasons -3 unable to contact 4000 IU daily (n=125) Completed 3 years of treatment (n=115) Discontinued treatment (n=10) -5 adverse events -4 personal reasons -1 unable to contact 10000 IU daily (n=124) Completed 3 years of treatment Supplement Table S1 . Baseline and absolute mean change (SD) from baseline by treatment group for medio-lateral (ML) sway index. ECFO eyes closed foam surface. p<0.05 significantly different from a baseline.
Nutrients 2020, 12, 527; doi:10.3390/nu12020527 www.mdpi.com/journal/nutrients Supplement Table S2 . Baseline and absolute mean change (SD) from baseline by treatment group for anterior-posterior (AP) sway index. Supplement Table S3 . Adjusted mean absolute difference (95% confidence interval) in mediolateral (ML) sway index between treatment groups using linear mixed effects modeling. Supplement Table S4 . Adjusted mean absolute difference (95% confidence interval) in anteriorposterior (AP) sway index between treatment groups using linear mixed effects modeling. 
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